GLP-2 (TZ)
Dual GIP/GLP-1 receptor agonist
A single-molecule dual agonist at the GIP and GLP-1 receptors, built on a GIP backbone. Released at ≥ 99 % HPLC with mass confirmation against 4813.45 Da.
Current lot verified
CP-TIRZEPPA-2607A · tested Jul 15, 2026
99.67 %
HPLC purity
About GLP-2 (TZ)
Tirzepatide is a 39-amino-acid synthetic peptide engineered on a GIP scaffold and modified to bind both the GIP and GLP-1 receptors from one molecule. A C20 fatty diacid conjugated through the lysine at position 20 provides albumin binding and the extended half-life that made weekly dosing schedules feasible in published trials. Its receptor pharmacology is asymmetric — it is a full agonist at GIPR and a biased partial agonist at GLP-1R — and that imbalance is itself an active area of research into which receptor contributes what.
Because the molecule is longer and more hydrophobic than semaglutide, it elutes late on reversed phase and is more prone to aggregation if reconstituted carelessly. We release lots only after a post-reconstitution clarity check in addition to the standard purity and identity panel.
Published research areas
- Dual incretin receptor pharmacology
- Biased agonism and receptor trafficking
- Adipocyte and hepatocyte metabolic models
- Comparative incretin studies
Specifications
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.45 g/mol
- Release specification
- ≥ 99.0 % by HPLC
- Appearance
- White lyophilised cake, low density
- Solubility
- Soluble in bacteriostatic water; brief warming to room temperature before reconstitution improves recovery
- Storage
- Lyophilised at -20 °C. Reconstituted at 2–8 °C, protected from light.
- Format
- lyophilized vial
Handling and reconstitution
Allow the vial to reach room temperature before adding diluent — cold glass promotes localised supersaturation and cloudy reconstitution.
Storage: Lyophilised at -20 °C. Reconstituted at 2–8 °C, protected from light.
Full reconstitution and storage referenceLot history
Every released lot of this compound, oldest kept on file. Average across 3 lots: 99.46 %.
| Lot | Strength | Purity | Tested | Laboratory | |
|---|---|---|---|---|---|
| CP-TIRZEPPA-2607A | 10 mg | 99.67 % | Jul 15, 2026 | Aurum Bioanalytics | Certificate → |
| CP-TIRZEPPA-2605B | 20 mg | 99.09 % | May 13, 2026 | Colmaric Analyticals | Certificate → |
| CP-TIRZEPPA-2603C | 30 mg | 99.61 % | Mar 6, 2026 | Colmaric Analyticals | Certificate → |
Selected literature
Listed for orientation. Citation is not endorsement of any outcome, and no claim is attached to any of these works.
Tirzepatide, a dual GIP and GLP-1 receptor agonist
Molecular Metabolism
Structural basis of dual incretin receptor engagement
Nature Communications
Questions about this compound
Usually not. Tirzepatide is hydrophobic and hazes if diluent is added too fast or the vial is cold. Bring it to room temperature, add diluent down the wall, and let it stand 10 minutes without agitation. If haze persists, send us the lot number — we will replace it.
Others in GLP & Metabolic
GLP & Metabolic
GLP-3 (RT)
Triple GIP/GLP-1/glucagon receptor agonist
From
$135
